Results from Phase 1 KPG-121 trial, a new cereblon modulator

[Maxone73]

KPG-121 is an experimental cereblon modulator aimed at metastatic castration-resistant prostate cancer (mCRPC). Early research shows it binds more strongly than lenalidomide to a key immune-regulating protein, potentially boosting anti-cancer effects. In a Phase 1 study of 16 mCRPC patients already taking abiraterone or enzalutamide, 75% experienced drug-related side effects like low blood counts, leading five to drop out. Yet initial efficacy signals emerged: out of eight patients with evaluable disease, 37.5% had partial responses and 37.5% had stable disease, translating to 75% disease control. Lower doses (1.5 and 2.5 mg) seemed more tolerable while still suggesting benefit. Although more trials are needed, KPG-121 may become a promising partner to existing hormonal therapies in advanced prostate cancer.

prostatewarriors.com/2025/0...